JP2007517904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517904A5 JP2007517904A5 JP2006549571A JP2006549571A JP2007517904A5 JP 2007517904 A5 JP2007517904 A5 JP 2007517904A5 JP 2006549571 A JP2006549571 A JP 2006549571A JP 2006549571 A JP2006549571 A JP 2006549571A JP 2007517904 A5 JP2007517904 A5 JP 2007517904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hept
- diazabicyclo
- independently
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 276
- -1 tetrahydronaphthalenyl Chemical group 0.000 claims 90
- 125000001424 substituent group Chemical group 0.000 claims 59
- 125000005843 halogen group Chemical group 0.000 claims 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 42
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims 38
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 38
- 229910052799 carbon Inorganic materials 0.000 claims 31
- 125000004043 oxo group Chemical group O=* 0.000 claims 28
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 25
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 18
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 18
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 18
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 18
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 18
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 18
- 125000002541 furyl group Chemical group 0.000 claims 18
- 125000002883 imidazolyl group Chemical group 0.000 claims 18
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 18
- 125000001041 indolyl group Chemical group 0.000 claims 18
- 125000001786 isothiazolyl group Chemical group 0.000 claims 18
- 125000000842 isoxazolyl group Chemical group 0.000 claims 18
- 125000002757 morpholinyl group Chemical group 0.000 claims 18
- 125000002971 oxazolyl group Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 125000004193 piperazinyl group Chemical group 0.000 claims 18
- 125000003386 piperidinyl group Chemical group 0.000 claims 18
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 18
- 125000004076 pyridyl group Chemical group 0.000 claims 18
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 18
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 18
- 125000000335 thiazolyl group Chemical group 0.000 claims 18
- 125000001544 thienyl group Chemical group 0.000 claims 18
- 125000001425 triazolyl group Chemical group 0.000 claims 18
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 17
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 16
- 125000001624 naphthyl group Chemical group 0.000 claims 16
- 125000000168 pyrrolyl group Chemical group 0.000 claims 14
- 125000004306 triazinyl group Chemical group 0.000 claims 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 13
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 12
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 12
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 12
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 12
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 12
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 9
- 125000002619 bicyclic group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 125000004434 sulfur atom Chemical group 0.000 claims 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 4
- 125000003047 N-acetyl group Chemical group 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 230000006044 T cell activation Effects 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 claims 2
- HUSCFUXDGASTLI-YDIPPGQESA-N 4-[5-[(1s,4s)-5-(2-phenoxypropyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC(C)OC=2C=CC=CC=2)[H])=CC=CC=C1 HUSCFUXDGASTLI-YDIPPGQESA-N 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- OLFFOWYNQJKLDU-SNRMKQJTSA-N 2-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-methyl-6-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]pyrimidin-4-one Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N(C(=O)C=2)C)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 OLFFOWYNQJKLDU-SNRMKQJTSA-N 0.000 claims 1
- MUSPLTOFMXRFOE-NDXORKPFSA-N 4-[2-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyridin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=CC=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 MUSPLTOFMXRFOE-NDXORKPFSA-N 0.000 claims 1
- BZLNQHVXJPCZCT-NYVOZVTQSA-N 4-[2-methylsulfanyl-6-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=C(SC)N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 BZLNQHVXJPCZCT-NYVOZVTQSA-N 0.000 claims 1
- PKWBFXMNHSZDTB-LNLFQRSKSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-[(1s)-1-(2-fluorophenyl)ethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1F PKWBFXMNHSZDTB-LNLFQRSKSA-N 0.000 claims 1
- TWYYQCKDAVLTKR-CUWPLCDZSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 TWYYQCKDAVLTKR-CUWPLCDZSA-N 0.000 claims 1
- VZMQHTHDLXOOET-YYWHXJBOSA-N 4-[4-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 VZMQHTHDLXOOET-YYWHXJBOSA-N 0.000 claims 1
- UXAGYDYQHFDNBY-NYVOZVTQSA-N 4-[4-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 UXAGYDYQHFDNBY-NYVOZVTQSA-N 0.000 claims 1
- RQGMJYSQCBDCMZ-VJBMBRPKSA-N 4-[4-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)CC)[H])=CC=CC=C1 RQGMJYSQCBDCMZ-VJBMBRPKSA-N 0.000 claims 1
- ZABHCFAMEITAHK-OYDLWJJNSA-N 4-[4-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)CC)[H])=CC=CC=C1 ZABHCFAMEITAHK-OYDLWJJNSA-N 0.000 claims 1
- FDAUXZFXTPDSRM-NYVOZVTQSA-N 4-[4-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 FDAUXZFXTPDSRM-NYVOZVTQSA-N 0.000 claims 1
- RVQIRCOGFQIAJJ-VJBMBRPKSA-N 4-[4-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 RVQIRCOGFQIAJJ-VJBMBRPKSA-N 0.000 claims 1
- YMPJQANVEGWILT-YYWHXJBOSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-n-[(1s)-1-naphthalen-1-ylethyl]pyridin-2-amine Chemical compound C1=CC=C2C([C@H](C)NC=3N=CC=C(C=3)C=3N=C(N4N=CN=C4C=3)N3C[C@]4(NC[C@]3([H])C4)[H])=CC=CC2=C1 YMPJQANVEGWILT-YYWHXJBOSA-N 0.000 claims 1
- JKVGSSMZDIFZSF-UXPWSPDFSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1r)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 JKVGSSMZDIFZSF-UXPWSPDFSA-N 0.000 claims 1
- XIXXFELFCFBDOU-OLKLTNODSA-N 4-[5-[(1s,4s)-2-butan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)CC)[H])=CC=CC=C1 XIXXFELFCFBDOU-OLKLTNODSA-N 0.000 claims 1
- BRIYHAYUDAJLJV-VJBMBRPKSA-N 4-[5-[(1s,4s)-2-tert-butyl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@@]2(C3)[H])C(C)(C)C)[H])=CC=CC=C1 BRIYHAYUDAJLJV-VJBMBRPKSA-N 0.000 claims 1
- NBMSKMMNDPHSAZ-DKICCIFJSA-N 4-[5-[(1s,4s)-3-methyl-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@@]3(C[C@@]2([H])C(C)N3C(C)C)[H])=CC=CC=C1 NBMSKMMNDPHSAZ-DKICCIFJSA-N 0.000 claims 1
- XHQNKBJBTQDUFF-ZVJDSTMCSA-N 4-[5-[(1s,4s)-5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]-3h-pyridin-4-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)CC(F)F)[H])N2C(N1C=CN=C1C=1)=NC=1C1(N[C@@H](C)C=2C=CC=CC=2)CC=NC=C1 XHQNKBJBTQDUFF-ZVJDSTMCSA-N 0.000 claims 1
- GUHQBASITAZOSX-OYDLWJJNSA-N 4-[5-[(1s,4s)-5-(2-methylpropyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC(C)C)[H])=CC=CC=C1 GUHQBASITAZOSX-OYDLWJJNSA-N 0.000 claims 1
- BBLOJEWCGIQPDH-YGPDHOBYSA-N 4-[5-[(1s,4s)-5-(2-phenoxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCOC=2C=CC=CC=2)[H])=CC=CC=C1 BBLOJEWCGIQPDH-YGPDHOBYSA-N 0.000 claims 1
- QGKQXIRIUYZUDY-CAVYSCNFSA-N 4-[5-[(1s,4s)-5-benzyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC=2C=CC=CC=2)[H])=CC=CC=C1 QGKQXIRIUYZUDY-CAVYSCNFSA-N 0.000 claims 1
- XKSYHHVIDRYCNU-OYDLWJJNSA-N 4-[5-[(1s,4s)-5-butyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCCC)[H])=CC=CC=C1 XKSYHHVIDRYCNU-OYDLWJJNSA-N 0.000 claims 1
- UALKGXILIOUUGQ-OPXMRZJTSA-N 4-[5-[(1s,4s)-5-cyclopentyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C2CCCC2)[H])=CC=CC=C1 UALKGXILIOUUGQ-OPXMRZJTSA-N 0.000 claims 1
- YWLVWOCNSRYDHO-YYWHXJBOSA-N 4-[5-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 YWLVWOCNSRYDHO-YYWHXJBOSA-N 0.000 claims 1
- MTFKWAAUPVJALN-SNRMKQJTSA-N 4-[6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-methylsulfanylpyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=C(SC)N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 MTFKWAAUPVJALN-SNRMKQJTSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- LYLWBIPQXXROQN-UHFFFAOYSA-N CC(C)N(CC1C2)C2CN1C1=NC(C2=CC=CN=C2NCC2=CC=CC3=CC=CC=C23)=CC2=NC=CN12 Chemical compound CC(C)N(CC1C2)C2CN1C1=NC(C2=CC=CN=C2NCC2=CC=CC3=CC=CC=C23)=CC2=NC=CN12 LYLWBIPQXXROQN-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021067 Hypopituitarism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000042846 PKC family Human genes 0.000 claims 1
- 108091082203 PKC family Proteins 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000008081 blood perfusion Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- CRZSXSCVAOQWRE-OYDLWJJNSA-N n-(2,2-dimethoxyethyl)-6-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]-2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(NCC(OC)OC)N=C(N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CRZSXSCVAOQWRE-OYDLWJJNSA-N 0.000 claims 1
- DTIGGPHKRSURDR-DQEYMECFSA-N n-(naphthalen-1-ylmethyl)-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1=CC=C2C(CNC=3N=CC=C(C=3)C=3N=C(N4C=CN=C4C=3)N3C[C@]4(N(C[C@]3([H])C4)C(C)C)[H])=CC=CC2=C1 DTIGGPHKRSURDR-DQEYMECFSA-N 0.000 claims 1
- ATQRNTSLYSZOSI-OIBXWCBGSA-N n-[(1r)-1-phenylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 ATQRNTSLYSZOSI-OIBXWCBGSA-N 0.000 claims 1
- AWAZGPBUVSVEEK-OYDLWJJNSA-N n-[(1s)-1-naphthalen-1-ylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1=CC=C2C([C@H](C)NC=3N=CC=C(C=3)C=3N=C(N4N=CN=C4C=3)N3C[C@]4(N(C[C@]3([H])C4)C(C)C)[H])=CC=CC2=C1 AWAZGPBUVSVEEK-OYDLWJJNSA-N 0.000 claims 1
- CHCSYRDEXKBZGG-YYWHXJBOSA-N n-[(1s)-1-phenylethyl]-4-[2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,3-thiazol-4-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(SC=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CHCSYRDEXKBZGG-YYWHXJBOSA-N 0.000 claims 1
- GKTBKKVWPNGMFG-NYVOZVTQSA-N n-[(1s)-1-phenylethyl]-4-[2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=CN=C(N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 GKTBKKVWPNGMFG-NYVOZVTQSA-N 0.000 claims 1
- CZSYKLHLDRGUJW-OYDLWJJNSA-N n-[(1s)-1-phenylethyl]-4-[3-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]indazol-1-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CZSYKLHLDRGUJW-OYDLWJJNSA-N 0.000 claims 1
- LWQDICDZDSPXPQ-OYDLWJJNSA-N n-[(1s)-1-phenylethyl]-4-[4-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]quinazolin-2-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 LWQDICDZDSPXPQ-OYDLWJJNSA-N 0.000 claims 1
- PYLNCHYZWPUCNK-TUSQITKMSA-N n-[(1s)-1-phenylethyl]-4-[4-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]quinolin-2-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 PYLNCHYZWPUCNK-TUSQITKMSA-N 0.000 claims 1
- DMVHEESFRSZGIP-OCPXOFMESA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-2-(1,1,1-trifluoropropan-2-yl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C(F)(F)F)[H])=CC=CC=C1 DMVHEESFRSZGIP-OCPXOFMESA-N 0.000 claims 1
- AIHQJENGTXVKMP-NYVOZVTQSA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3N=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 AIHQJENGTXVKMP-NYVOZVTQSA-N 0.000 claims 1
- FQVUVUVONWTCJN-VJBMBRPKSA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-5-propyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCC)[H])=CC=CC=C1 FQVUVUVONWTCJN-VJBMBRPKSA-N 0.000 claims 1
- TZRHQHMCEFZZPQ-SFTDATJTSA-N n-[(2-fluorophenyl)methyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NCC1=CC=CC=C1F TZRHQHMCEFZZPQ-SFTDATJTSA-N 0.000 claims 1
- SIIQBMIBASOKOD-ICSRJNTNSA-N n-benzyl-4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-fluoroindazol-1-yl]pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=C(F)C=C11)=NN1C(C=1)=CC=NC=1NCC1=CC=CC=C1 SIIQBMIBASOKOD-ICSRJNTNSA-N 0.000 claims 1
- RSWBCBOTSKKQOL-VXKWHMMOSA-N n-benzyl-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NCC1=CC=CC=C1 RSWBCBOTSKKQOL-VXKWHMMOSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000017983 photosensitivity disease Diseases 0.000 claims 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000004335 respiratory allergy Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010040400 serum sickness Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- VBRRTWCBLMRCLU-OYDLWJJNSA-N tert-butyl (1s,4s)-5-[1-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]indazol-3-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(N(C[C@]2([H])C3)C(=O)OC(C)(C)C)[H])=CC=CC=C1 VBRRTWCBLMRCLU-OYDLWJJNSA-N 0.000 claims 1
- FQJRZOYTUCCBQR-UHFFFAOYSA-N tert-butyl 2-methylheptanoate Chemical compound CCCCCC(C)C(=O)OC(C)(C)C FQJRZOYTUCCBQR-UHFFFAOYSA-N 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 208000005057 thyrotoxicosis Diseases 0.000 claims 1
- 230000024664 tolerance induction Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 238000002689 xenotransplantation Methods 0.000 claims 1
- 0 C*C(N1*)=NC(C)=C(*)C1=O Chemical compound C*C(N1*)=NC(C)=C(*)C1=O 0.000 description 4
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N Cc1cc(C)ncc1 Chemical compound Cc1cc(C)ncc1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
- PMCOWOCKUQWYRL-UHFFFAOYSA-N Cc1ccnc(C)n1 Chemical compound Cc1ccnc(C)n1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53661704P | 2004-01-14 | 2004-01-14 | |
| US11/034,042 US7582631B2 (en) | 2004-01-14 | 2005-01-11 | Substituted heterocyclic compounds and methods of use |
| PCT/US2005/000993 WO2005070934A1 (en) | 2004-01-14 | 2005-01-12 | Substituted diazabicycloheptanes and their use as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517904A JP2007517904A (ja) | 2007-07-05 |
| JP2007517904A5 true JP2007517904A5 (https=) | 2008-02-28 |
Family
ID=34810481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549571A Withdrawn JP2007517904A (ja) | 2004-01-14 | 2005-01-12 | 置換された複素環化合物及び使用の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7582631B2 (https=) |
| EP (1) | EP1727821A1 (https=) |
| JP (1) | JP2007517904A (https=) |
| AU (1) | AU2005206524B2 (https=) |
| CA (1) | CA2553232A1 (https=) |
| WO (1) | WO2005070934A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070148628A1 (en) * | 2005-12-09 | 2007-06-28 | Philadelphia College Of Osteopathic Medicine | Organ preservation and/or perfusion |
| EP1984351A1 (en) * | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| US8288366B2 (en) | 2006-06-20 | 2012-10-16 | Chochinov Ronald H | Formulation for hair growth |
| WO2008116185A2 (en) * | 2007-03-21 | 2008-09-25 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
| US20090023925A1 (en) * | 2007-06-28 | 2009-01-22 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
| CN101801194A (zh) * | 2007-08-15 | 2010-08-11 | 记忆医药公司 | 具有5-ht6受体亲和力的3’取代的化合物 |
| BRPI0908807A2 (pt) * | 2008-02-15 | 2015-07-28 | Hoffmann La Roche | Derivados de 3-alquil-piperazina e usos dos mesmos |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20120316182A1 (en) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| TW201332989A (zh) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| KR102215272B1 (ko) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
| WO2014093230A2 (en) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| ES2851724T3 (es) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Modulación de células madre |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
| EP3190889B1 (en) | 2014-09-03 | 2021-11-17 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| TWI726968B (zh) * | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| ES2924359T3 (es) * | 2017-04-11 | 2022-10-06 | Sunshine Lake Pharma Co Ltd | Compuestos de indazol sustituidos con flúor y usos de los mismos |
| RU2020133727A (ru) * | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| CN112881542B (zh) * | 2020-10-28 | 2022-11-18 | 上海安谱实验科技股份有限公司 | 一种稳定同位素氘标记的达氟沙星及其合成方法 |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| DE19610882A1 (de) * | 1996-03-20 | 1997-09-25 | Dresden Arzneimittel | Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| MXPA04010966A (es) | 2002-05-07 | 2005-01-25 | Neurosearch As | Derivados novedosos de biarilo diazabiciclico. |
| US20040242613A1 (en) | 2003-01-30 | 2004-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
| EP1454908B1 (en) | 2003-03-07 | 2008-02-27 | Sanofi-Aventis | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives |
| NZ551712A (en) * | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
-
2005
- 2005-01-11 US US11/034,042 patent/US7582631B2/en active Active
- 2005-01-12 EP EP05705583A patent/EP1727821A1/en not_active Withdrawn
- 2005-01-12 CA CA002553232A patent/CA2553232A1/en not_active Abandoned
- 2005-01-12 AU AU2005206524A patent/AU2005206524B2/en not_active Expired - Fee Related
- 2005-01-12 JP JP2006549571A patent/JP2007517904A/ja not_active Withdrawn
- 2005-01-12 WO PCT/US2005/000993 patent/WO2005070934A1/en not_active Ceased
-
2009
- 2009-02-04 US US12/322,671 patent/US20090149468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517904A5 (https=) | ||
| US12030885B2 (en) | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | |
| EP3183247B1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| US9550796B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| US9346810B2 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| JP2022528562A5 (https=) | ||
| JP2023549055A (ja) | 複素環式スピロ化合物及びその使用方法 | |
| US20240059703A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2007517904A (ja) | 置換された複素環化合物及び使用の方法 | |
| NZ580904A (en) | Amino-heterocyclic compounds for inhibiting pde9 | |
| US10208066B2 (en) | Imidazopyridazine compounds and their use | |
| EP3668858A1 (en) | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives | |
| US12473303B2 (en) | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | |
| IL273983B2 (en) | Concentrated imidazole derivatives substituted by tertiary hydroxy groups as p13k-gamma inhibitors | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| RU2022101112A (ru) | Бициклические гетероциклические соединения в качестве ингибиторов активности bcdin3d |